Fortress Biotech, Inc. FBIO
1.88 USD -0.11 (-5.53%)
At closeNov 13, 2026, 4:00 PM EST
1.88 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
1.76 Day range 1.94
1.76 52-week range 4.53
- YTD
- -48.63%
- 1 year
- -24.50%
News
fool.com Fortress Biotech: 3 Key Takeaways for Long-Term Investors Total revenue increased 8% to $19 million in the third quarter. Emrosi net sales reached $9 million on 40,000 total prescriptions.
benzinga.com Fortress Biotech Q3 EPS $(0.23) Misses $(0.15) Estimate, Sales $19.159M Miss $21.575M Estimate Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 309.09 percent decrease over earnings…
globenewswire.com Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025
seekingalpha.com Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call Transcript Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call Transcript
marketbeat.com Fortress Biotech Q3 Earnings Call Highlights Journey Medical reported third-quarter revenue of $19 million and a narrower net loss as sales of its rosacea treatment EMROSI grew and the company expanded insurance coverage for the drug.
globenewswire.com Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $19.0 million for the third quarter of 2026 Emrosi ® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to hold conference call today at 4:30…
globenewswire.com Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) MIAMI, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to…
globenewswire.com Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and…
defenseworld.net Johnson & Johnson (NYSE:JNJ) vs. Fortress Biotech (NASDAQ:FBIO) Head to Head Review Fortress Biotech (NASDAQ: FBIO - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
defenseworld.net Contrasting RYTHM (NASDAQ:RYM) and Fortress Biotech (NASDAQ:FBIO) RYTHM (NASDAQ: RYM - Get Free Report) and Fortress Biotech (NASDAQ: FBIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
globenewswire.com Journey Medical Corporation to Participate in September 2026 Investor Conferences SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and…
globenewswire.com Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
globenewswire.com Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130…
seekingalpha.com Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
prnewswire.com SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Fortress Biotech, Inc. (NASDAQ: FBIO) concerning possible breaches of fiduciary duties. If…
globenewswire.com Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in
globenewswire.com Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys…
seekingalpha.com Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and recent financial improvements. FBIO's Q1 2026 saw a dramatic cash increase to $255.8M and net profit…
seekingalpha.com Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily…
globenewswire.com Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on…
benzinga.com Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of…
benzinga.com Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of…
benzinga.com Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric…- benzinga.com HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.
- benzinga.com Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has…
benzinga.com Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.42) by 126.19 percent. This is a 114.47 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com Fortress Biotech And Cyprium Therapeutics Announce FDA Issues CRL Relating To NDA For CUTX-101, Intended To Treat Menkes Disease In Pediatric Patients Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17 HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price target from $26 to $17.
- benzinga.com CORRECTION: Fortress Biotech Q2 Adj. EPS $(0.46) Misses $(0.36) Estimate, Sales $16.413M Beat $14.534M Estimate Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36) by 27.78 percent. This is a 36.99 percent increase over losses of…
- benzinga.com Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying
- benzinga.com Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday
- benzinga.com Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update.
- benzinga.com Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in…
- benzinga.com Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.
- benzinga.com Why Direct Digital Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket Shares of Direct Digital Holdings, Inc. (NASDAQ: DRCT) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 99 stocks hit new 52-week lows.
benzinga.com Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer…- benzinga.com Earnings Scheduled For May 26, 2023 Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earnings for its first quarter.
- benzinga.com Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers CaliberCos Inc. (NASDAQ: CWD) shares jumped 65.6% to $9.94 amid post-IPO volatility.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 116 companies set new 52-week lows.